A detailed history of Rhumbline Advisers transactions in Maxcyte, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 151,253 shares of MXCT stock, worth $536,948. This represents 0.0% of its overall portfolio holdings.

Number of Shares
151,253
Previous 157,616 4.04%
Holding current value
$536,948
Previous $617,000 4.7%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$3.68 - $5.06 $23,415 - $32,196
-6,363 Reduced 4.04%
151,253 $588,000
Q2 2024

Aug 01, 2024

BUY
$3.63 - $5.0 $75,736 - $104,320
20,864 Added 15.26%
157,616 $617,000
Q1 2024

May 09, 2024

BUY
$3.94 - $5.38 $15,369 - $20,987
3,901 Added 2.94%
136,752 $572,000
Q4 2023

Feb 08, 2024

BUY
$2.6 - $5.24 $3,751 - $7,561
1,443 Added 1.1%
132,851 $624,000
Q3 2023

Nov 09, 2023

SELL
$3.02 - $5.1 $274 - $464
-91 Reduced 0.07%
131,408 $409,000
Q2 2023

Aug 08, 2023

SELL
$3.69 - $5.35 $13,446 - $19,495
-3,644 Reduced 2.7%
131,499 $603,000
Q1 2023

May 11, 2023

BUY
$4.03 - $5.89 $28,500 - $41,654
7,072 Added 5.52%
135,143 $669,000
Q4 2022

Feb 14, 2023

BUY
$4.92 - $7.4 $7,301 - $10,981
1,484 Added 1.17%
128,071 $699,000
Q3 2022

Nov 10, 2022

BUY
$4.52 - $6.51 $33,461 - $48,193
7,403 Added 6.21%
126,587 $823,000
Q2 2022

Aug 11, 2022

BUY
$3.59 - $6.81 $51,358 - $97,423
14,306 Added 13.64%
119,184 $564,000
Q1 2022

May 12, 2022

BUY
$5.26 - $10.84 $58,827 - $121,234
11,184 Added 11.94%
104,878 $733,000
Q4 2021

Feb 10, 2022

BUY
$8.87 - $12.94 $735,828 - $1.07 Million
82,957 Added 772.63%
93,694 $955,000
Q3 2021

Nov 12, 2021

BUY
$12.21 - $17.2 $131,098 - $184,676
10,737 New
10,737 $131,000

Others Institutions Holding MXCT

About MAXCYTE, INC.


  • Ticker MXCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 101,724,000
  • Market Cap $361M
  • Description
  • MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...
More about MXCT
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.